Given the known link between high RFX6 expression and poor clinical prognosis in PCa, as well as its roles in disease progression, we investigated whether increased RFX6 expression may lead to resistance during enzalutamide treatment. The gene discussed is RFX6; the disease is posterior cortical atrophy.